[New drugs of treatment of patients with chronic hepatitis B].
There are five approved drugs for the treatment of chronic hepatitis B(lamivudine, adefovir dipivoxil [ADV], entecavir [ETV], as well as pegylated and standard interferon) in Japan. In this paper, the reported data of new four drugs(tenofovir disoproxil fumarate [TDF], telbivudine, emtricitabine [FTC], clevudine) were described. TDF demonstrated potent antiviral efficacy in naive patients. Moreover, TDF is efficacious in lamivudine- or ADV-refractory patients. TDF monotherapy and the combination of FTC and TDF had similar efficacy in patients with incomplete viral suppression after therapy with ADV; response was not influenced by the presence of baseline lamivudine- or ADV-associated mutations.